Acetylsalicylic acid ( ASA ) did not reduce stroke or ‘ all cardiovascular events ’ compared to placebo in primary prevention patients with elevated BP and no prior cardiovascular disease .
To conclude for primary prevention in patients with elevated BP , antiplatelet therapy with ASA can not be recommended since the magnitude of benefit , a reduction in myocardial infa rct ion , is negated by a harm of similar magnitude , an increase in major haemorrhage .
Although elevated systemic blood pressure ( BP ) results in high intravascular pressure , the main complications of hypertension are related to thrombosis rather than haemorrhage .
It therefore seemed plausible that use of antithrombotic therapy may be useful in preventing thrombosis-related complications of elevated BP .
The objectives were to conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with BP , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .
Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study.
Thirty-seven patients affected by polycythaemia rubra vera ( PRV ) and with at least one additional thrombotic risk factor ( overt vascular disease , diabetes mellitus , treated hypertension , smoking habit , plasma hyperviscosity , hyperfibrinogenemia ) were enrolled in a double-blind r and omized placebo-controlled study , and 18 were given ticlopidine 250 mg , b.i.d . , for 60 days . All the patients had previously been su bmi tted to cytoreduction , and PRV was under control in all cases at the start of the study . During the study , the haematological parameters were controlled every 15 days , and venesection was performed if haematocrit was greater than 46 % . Whole blood viscosity , at low and high shear rates , plasma viscosity , and fibrinogen were measured on days 0 and 60 . In the ticlopidine group , we recorded a significant 13.14 % reduction of the mean fibrinogen level after treatment ( 390 + /- 63 vs. 449 + /- 97 mg/dl , p less than 0.01 ) . All the other haemorheological parameters were not significantly modified by ticlopidine treatment , nor were there significant modifications recorded in the placebo group . Our study shows that ticlopidine may reduce a probable thrombotic risk factor ( hyperfibrinogenemia ) in PRV patients
Acetylsalicylic acid ( ASA ) did not reduce stroke or ‘ all cardiovascular events ’ compared to placebo in primary prevention patients with elevated BP and no prior cardiovascular disease .
To conclude for primary prevention in patients with elevated BP , antiplatelet therapy with ASA can not be recommended since the magnitude of benefit , a reduction in myocardial infa rct ion , is negated by a harm of similar magnitude , an increase in major haemorrhage .
Although elevated systemic blood pressure ( BP ) results in high intravascular pressure , the main complications of hypertension are related to thrombosis rather than haemorrhage .
It therefore seemed plausible that use of antithrombotic therapy may be useful in preventing thrombosis-related complications of elevated BP .
The objectives were to conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with BP , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .